Business - Briefly   

Dr. Reddy's in pact with Rheoscience

HYDERABAD: Dr. Reddy's Laboratories has entered into a co-development and commercialisation agreement with Denmark-based Rheoscience A/S for the joint development and commercialisation of balaglitazone (DRF 2593), a partial PPAR-gamma agonist for the treatment of type 2 diabetes. Under the agreement, Rheoscience will fund all the costs associated with the Phase III clinical trials of DRF 2593 and Dr. Reddy's will pay Rheoscience a pre-determined amount towards its share of the development costs.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

UTI AMC sale to 4 sponsors cleared
SBICAP's retail foray
Chambers criticise strike
Nipuna achieves eSCM level 4
PACs to emerge as automation standard
DCI maintains 120 p. c. dividend
India a favourite for FDI
Rupee gains further against $
Sensex hits a new high
Exchange rates
Bullion rates
Gold shoots up
India's InIP improves
Taj group to set up hotel in Agartala
Unibic to use Bradman's name
Set up consumer redressal mechanism
Chola MF launches tax saver fund
Principal PNB's new mutual fund scheme
Central Bank merges three RRBs
Geojit opens office in Erode
SAAG RR Infra bags order
Dr. Reddy's in pact with Rheoscience
Pervasive opens development centre
RMG Group forms venture with Autometers
SatNav Technologies to enter West Asian market
Jataayu's new version of IMPS
Berger Paints undergoes re-branding exercise
LG launches `Mangal hi Mangal' festival offer
Hutch expands operations in Uttaranchal
Principal PNB's new mutual fund scheme
Central Bank merges three RRBs

Copyright © 2005, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu